

## Teva – Recall of metformin extended-release (ER)

- On June 2, 2020, [Teva announced](#) a voluntary, consumer-level recall of 14 lots of [metformin ER](#) tablets due to the detection of N-nitrosodimethylamine (NDMA) levels in excess of the acceptable daily intake limit.
- NDMA is classified as a probable human carcinogen based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
- The recalled lots were packaged under the Actavis Pharma label and distributed in the U.S. between January 8, 2019 and May 27, 2020.

Product Description	NDC#	Lot# (Expiration Date)
Metformin Hydrochloride Extended-Release 500 mg tablets	62037-571-01	1329548A (06/2020); 1338302M (10/2020); 1348968M (10/2020); 1348969M (11/2020); 1348970M (10/2020); 1376339M (09/2021)
	62037-571-10	1323460M (06/2020); 1330919M (06/2020); 1338300A (10/2020); 1341135M (12/2020); 1391828M (11/2021)
Metformin Hydrochloride Extended-Release 750 mg tablets	62037-577-01	1333338M (08/2020); 1333339A (08/2020)
	62037-577-10	1354471A (02/2021)

- Metformin ER tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.
- Patients who have the recalled metformin ER should continue taking it and contact their physician or healthcare provider to prescribe a replacement.
- Health care professionals should continue to prescribe metformin when clinically appropriate. FDA testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- The FDA continues to evaluate the safety of metformin and will provide more information as it becomes available. Updates can be found [here](#).

- Contact Teva Medical Information by phone at **1-888-838-2872** or by email at **druginfo@tevapharm.com** for further information regarding this recall.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.